摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-dimethylamino-4-(naphth-1-yl)oxazole | 583860-13-3

中文名称
——
中文别名
——
英文名称
2-dimethylamino-4-(naphth-1-yl)oxazole
英文别名
N,N-dimethyl-4-naphthalen-1-yl-1,3-oxazol-2-amine
2-dimethylamino-4-(naphth-1-yl)oxazole化学式
CAS
583860-13-3
化学式
C15H14N2O
mdl
——
分子量
238.289
InChiKey
CNRYKDJRCASTBP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.7
  • 重原子数:
    18
  • 可旋转键数:
    2
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.13
  • 拓扑面积:
    29.3
  • 氢给体数:
    0
  • 氢受体数:
    3

反应信息

  • 作为产物:
    参考文献:
    名称:
    5-HT2B receptor antagonists
    摘要:
    本发明涉及包括公式I化合物的化合物:或其药用可接受的盐,其中R1和R4之一选自由H、以及可选地取代的C1-6烷基、C3-7环烷基、C3-7环烷基-C1-4烷基和苯基-C1-4烷基组成的组;而R1和R4中的另一个是可选地取代的C9-14芳基基团;R2和R3是:(i)独立地选自H、R、R′、SO2R、C(═O)R、(CH2)nNR5R6,其中n是从1到4,而R5和R6独立地选自H和R,其中R是可选地取代的C1-4烷基,而R′是可选地取代的苯基-C1-4烷基,或(ii)与它们所连接的氮原子一起,形成一个可选地取代的C5-7杂环基团。这些化合物可用于治疗包括可以通过对抗5-HT2B受体而缓解的条件,如胃肠道疾病和充血性心力衰竭。
    公开号:
    US20050176791A1
点击查看最新优质反应信息

文献信息

  • 2-OXAZOLAMINES AND THEIR USE AS 5-HT2B RECEPTOR ANTAGONISTS
    申请人:ASTERAND UK LIMITED
    公开号:EP1474140B1
    公开(公告)日:2007-11-21
  • US7429607B2
    申请人:——
    公开号:US7429607B2
    公开(公告)日:2008-09-30
  • [EN] 2-OXAZOLAMINES AND THEIR USE AS 5-HT2B RECEPTOR ANTAGONISTS<br/>[FR] 2-OXAZOLAMINES ET LEUR UTILISATION COMME ANTAGONISTES DU RECEPTEUR 5-HT2B
    申请人:PHARMAGENE LAB LTD
    公开号:WO2003068226A1
    公开(公告)日:2003-08-21
    The present invention relates to compounds of formula (I): wherein one of R1 and R4 is selected from the group consisting of H, and optionally substituted C1-6 alkyl, C3-7 cycloalkyl, C3-7 cycloalkyl-C1-4 alkyl, and phenyl-C1-4 alkyl; and the other of R1 and R4 is an optionally substituted C9-14 aryl group; R2 and R3 are either:(i) independently selected from H, R, R', SO2R, C(=O)R, (CH2)nNR5R6, where n is from 1 to 4 and R5 and R6 are independently selected from H and R, where R is optionally substituted C1-4 alkyl, and R' is optionally substituted phenyl-C1-4 alkyl, or (ii) together with the nitrogen atom to which they are attached, form an optionally substituted C5-7 heterocyclic group; and their use as pharmaceuticals, in particular for treating conditions alleviated by the antagonism of a 5-HT2B receptor.
  • [EN] USE OF 5-HT2B RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CONGESTIVE HEART FAILURE<br/>[FR] UTILISATION D'ANTAGONISTES DU RECEPTEUR 5-HT2B DANS LE TRAITEMENT DE L'INSUFFISANCE CARDIAQUE GLOBALE
    申请人:PHARMAGENE LAB LTD
    公开号:WO2005016338A1
    公开(公告)日:2005-02-24
    The use of a 5HT2B receptor antagonist for the manufacture of a medicament for the treatment of congestive heart failure.
  • 5-HT2B receptor antagonists
    申请人:——
    公开号:US20040010022A1
    公开(公告)日:2004-01-15
    The present invention relates to compounds of formula I: 1 wherein one of R 1 and R 4 is selected from the group consisting of H, and optionally substituted C 1-6 alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkyl-C 1-4 alkyl, and phenyl-C 1-4 alkyl; and the other of R 1 and R 4 is an optionally substituted C 9-14 aryl group; R 2 and R 3 are either: (i) independently selected from H, R, R′, SO 2 R, C(═O)R, (CH 2 ) n NR 5 R 6 , where n is from 1 to 4 and R 5 and R 6 are independently selected from H and R, where R is optionally substituted C 1-4 alkyl, and R′ is optionally substituted phenyl-C 1-4 alkyl, or (ii) together with the nitrogen atom to which they are attached, form an optionally substituted C 5-7 heterocyclic group; and their use as pharmaceuticals, in particular for treating conditions alleviated by the antagonism of a 5-HT 2B receptor.
    本发明涉及公式I的化合物: 1 其中R 1 和R 4 之一选自由H、以及可选地取代的C 1-6 烷基、C 3-7 环烷基、C 3-7 环烷基-C 1-4 烷基和苯基-C 1-4 烷基组成的组;R 1 和R 4 的另一个是可选地取代的C 9-14 芳基基团;R 2 和R 3 是: (i)独立地选自H、R、R′、SO 2 R、C(═O)R、(CH 2 ) n NR 5 R 6 ,其中n是从1到4,R 5 和R 6 独立地选自H和R,其中R是可选地取代的C 1-4 烷基,R′是可选地取代的苯基-C 1-4 烷基,或 (ii)与它们连接的氮原子一起,形成一个可选地取代的C 5-7 杂环基团;以及它们作为药物的使用,特别用于治疗通过5-HT 2B 受体的拮抗作用减轻的状况。
查看更多